about
Repeated nipple fluid aspiration: compliance and feasibility results from a prospective multicenter studyMolecular analysis of nipple fluid for breast cancer screening.DNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detectionMethylation is less abundant in BRCA1-associated compared with sporadic breast cancer.Methylation profiles of hereditary and sporadic ovarian cancer.Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.Diarrhoea during checkpoint blockade, not always colitis.Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer.Comparison of different promoter methylation assays in breast cancer.Low levels of BNIP3 promoter hypermethylation in invasive breast cancer.The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α[Epigenetic processes in malignant transformation: the role of DNA methylation in cancer development]Oxytocin: bringing magic into nipple aspirationPhysical activity in relation to mammographic density in the dutch prospect-European prospective investigation into cancer and nutrition cohortResponse to A. Matikas et alReal-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The NetherlandsVemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomesCerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibitionAcute-Onset Pneumonitis while Administering the First Dose of DurvalumabDark ascites, an ovarian mass and a black dotted peritoneum[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry]Targeted Therapy in Advanced Melanoma With Rare BRAF MutationsSwitching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment RegistryAssociation of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment RegistryHealthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted DrugsSurgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy
P50
Q35637243-49393C8D-6C29-49EB-9ECA-A58AE45B1267Q37188295-77D791C4-F754-43EB-A11F-0589560DD575Q37269445-71E26E64-7139-46A1-A3AC-FEEA11D73BE8Q37321816-6ACB6763-17C5-4472-8E7F-A2D1E1BC752CQ39837903-7E3557E0-2F57-4E16-8A81-84E67C9898A7Q40204803-A368E7DB-4D6E-4A52-9929-49FB642F4AADQ47675540-9C527FB4-BAEC-4914-B517-E3953302F0FFQ50120368-5281AD56-BCB6-4F3B-ABA1-0B0E73D29DD0Q54504122-63FA7AF4-D028-48D3-A3C7-1CAFA256EBBEQ54964100-63539267-AE84-4374-947C-F4F6A120850EQ55261932-52C77C1E-1E94-4F30-B316-B1E0F968B2E2Q63987371-8EFB1F41-3A7D-4B27-A5D7-9D698214BCFBQ80329312-04ABC6BF-C56F-4A92-95B6-786F5026B417Q81039497-56CD9C65-26CD-473A-B3FA-73BE22D8FFF4Q82827943-30B12DD4-FA18-4468-B448-343EF01071C1Q88265837-A5C1E230-FFDA-4B40-BACA-899C7D1AC653Q88317126-1042BB4C-82A1-41D1-80F2-5A35B1ECAFE7Q88640780-F7BD1193-66AE-4AD9-8DAA-46A5464AA752Q90110804-B2BBE00F-9821-4DB7-BE66-0A2964D80A7BQ90206290-30381F21-37A8-45AB-97D7-FF57DBA95E59Q90224076-F8AB02E2-3DA9-484E-AB5B-4C16F192EAC6Q90439640-C702ABF4-9881-4E1E-BD07-D51A63A2507BQ90455755-354C7B00-A9D7-4338-9B7E-A90D7AEBA3B8Q91809931-ECFE32E1-A168-405F-B33B-C267CB07D290Q92026392-C3C79AC7-21D6-4053-A523-6A3B7B07DBF9Q92977397-05C000D7-63BF-4E83-9E50-4809E419AB02Q93184557-A0FBFB0B-0339-4309-A12A-6AC40703F901Q94556050-DF41E2FE-6A5D-4731-A15D-447F8EED038F
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Karijn P. Suijkerbuijk
@en
Karijn P. Suijkerbuijk
@nl
type
label
Karijn P. Suijkerbuijk
@en
Karijn P. Suijkerbuijk
@nl
altLabel
Suijkerbuijk KP
@en
prefLabel
Karijn P. Suijkerbuijk
@en
Karijn P. Suijkerbuijk
@nl
P31
P496
0000-0003-3604-5430